Shared on06 Aug 25Fair value Increased 27%
IDEXX Laboratories’ consensus price target has been sharply raised, reflecting strengthened revenue growth forecasts and a higher future P/E multiple, with fair value increasing from $542.55 to $657.55. What's in the News IDEXX Laboratories raised 2025 earnings guidance, increasing revenue outlook to $4,205–$4,280 million (up $90 million at midpoint) and EPS to $12.40–$12.76 (up $0.40 at midpoint), reflecting strong recurring diagnostics revenue, higher inVue Dx instrument placements, and favorable foreign exchange.
Shared on30 Apr 25Fair value Increased 3.42%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on23 Apr 25Fair value Decreased 1.44%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on16 Apr 25Fair value Decreased 0.69%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on09 Apr 25Fair value Decreased 0.28%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on02 Apr 25Fair value Increased 1.67%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on26 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on19 Mar 25Fair value Decreased 0.23%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on10 Mar 25Fair value Decreased 4.22%
AnalystConsensusTarget made no meaningful changes to valuation assumptions.